ATE401892T1 - Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand - Google Patents

Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand

Info

Publication number
ATE401892T1
ATE401892T1 AT00983101T AT00983101T ATE401892T1 AT E401892 T1 ATE401892 T1 AT E401892T1 AT 00983101 T AT00983101 T AT 00983101T AT 00983101 T AT00983101 T AT 00983101T AT E401892 T1 ATE401892 T1 AT E401892T1
Authority
AT
Austria
Prior art keywords
futting
state
pharmaceutical preparations
preparations containing
containing oxcarbazepine
Prior art date
Application number
AT00983101T
Other languages
English (en)
Inventor
Steffen Lang
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE401892T1 publication Critical patent/ATE401892T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00983101T 1999-11-02 2000-10-31 Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand ATE401892T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925962.4A GB9925962D0 (en) 1999-11-02 1999-11-02 Organic compounds

Publications (1)

Publication Number Publication Date
ATE401892T1 true ATE401892T1 (de) 2008-08-15

Family

ID=10863836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983101T ATE401892T1 (de) 1999-11-02 2000-10-31 Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand

Country Status (25)

Country Link
US (3) US20060079502A1 (de)
EP (1) EP1242091B1 (de)
JP (3) JP2003514780A (de)
KR (1) KR100493836B1 (de)
CN (1) CN1407894A (de)
AT (1) ATE401892T1 (de)
AU (1) AU777705B2 (de)
BR (1) BR0015188A (de)
CA (1) CA2388609C (de)
CZ (1) CZ302847B6 (de)
DE (1) DE60039629D1 (de)
ES (1) ES2311001T3 (de)
GB (1) GB9925962D0 (de)
HK (1) HK1050839B (de)
HU (1) HU227685B1 (de)
IL (3) IL149147A0 (de)
MX (1) MXPA02004389A (de)
NO (1) NO330947B1 (de)
NZ (1) NZ518378A (de)
PL (1) PL200273B1 (de)
RU (1) RU2330666C2 (de)
SK (1) SK287479B6 (de)
TR (1) TR200200951T2 (de)
WO (1) WO2001032183A2 (de)
ZA (1) ZA200203394B (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
EP1509207B1 (de) * 2002-05-31 2009-04-29 Desitin Arzneimittel GmbH Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
AU2003266965A1 (en) * 2002-08-06 2004-02-25 Novartis Ag Use of carboxamides for the treatment of tinnitus
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
BRPI0414112A (pt) * 2003-09-03 2006-10-31 Novartis Ag uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US20090196919A1 (en) * 2004-10-25 2009-08-06 Ajay Singla Oxcarbazepine dosage forms
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
US20090143360A1 (en) * 2005-07-08 2009-06-04 Muhammed Safadi Oxcarbazepine Formulation
WO2007029093A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of oxcarbazepine
CN101336105A (zh) * 2006-01-31 2008-12-31 特瓦制药工业有限公司 奥卡西平药物制剂及其制备方法，其中奥卡西平具有宽且多峰的粒度分布
EP2029118A2 (de) * 2006-01-31 2009-03-04 Teva Pharmaceutical Industries, Inc. Pharmazeutische formulierung von oxcarbazepin und ihr herstellungsverfahren, wobei oxcarbazepin eine breite und multimodale teilchengrössenverteilung aufweist
ES2360423T3 (es) * 2006-04-26 2011-06-03 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal.
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
ES2559838T3 (es) 2007-03-16 2016-02-16 Concert Pharmaceuticals, Inc. Inhibidores de proteína de transferencia de ésteres de colesterol
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
JP2010524972A (ja) * 2007-04-19 2010-07-22 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化したモルホリニル化合物
EP2152689B1 (de) 2007-04-25 2013-01-02 Concert Pharmaceuticals Inc. Analoga von cilostazol
EP3632916B1 (de) 2007-05-01 2022-06-08 Concert Pharmaceuticals Inc. Morphinanverbindungen
PL2522668T3 (pl) 2007-05-01 2015-07-31 Concert Pharmaceuticals Inc Związki morfinanu
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
PL2792662T3 (pl) 2007-05-01 2016-10-31 Związki morfinanu
ES2395137T3 (es) 2007-06-12 2013-02-08 Concert Pharmaceuticals, Inc. Derivados de azapéptidos como inhibidores de la proteasa VIH
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2716788C (en) 2008-02-29 2016-08-16 Concert Pharmaceuticals, Inc. Deuterium-substituted xanthine derivatives
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
KR101716512B1 (ko) 2008-09-19 2017-03-14 콘서트 파마슈티컬즈, 인크. 모르피난 화합물
EP2397159A3 (de) 2008-10-30 2012-02-22 Concert Pharmaceuticals, Inc. Kombination von Morphinan-Verbindungen und Antidepressiva zur Behandlung von hartnäckigen und chronischen Schmerzen
EP3090760A1 (de) 2008-10-30 2016-11-09 Concert Pharmaceuticals, Inc. Kombination von morphinanverbindungen und antidepressivum zur behandlung von pseudobulbärer affektstörung, neurologischen erkrankungen, hartnäckigen und chronischen schmerzen und gehirnverletzungen
WO2010053550A2 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2408771B1 (de) 2009-03-17 2016-11-16 Concert Pharmaceuticals, Inc. Pyrazinoisochinolinverbindungen
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
US8501738B2 (en) 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
US20140018379A1 (en) 2010-02-18 2014-01-16 Concert Pharmaceuticals Inc. Pyrimidine derivatives
WO2011106703A2 (en) 2010-02-26 2011-09-01 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
EP2542534A1 (de) 2010-03-02 2013-01-09 Concert Pharmaceuticals Inc. Deuterierte tetrahydronaphthalenderivate
EP2616467A1 (de) 2010-09-13 2013-07-24 Concert Pharmaceuticals Inc. Substituierte azaindole
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
CA2828251A1 (en) 2011-02-25 2012-08-30 Concert Pharmaceuticals, Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
AU2012255711B2 (en) 2011-05-18 2017-05-04 Vertex Pharmaceuticals (Europe) Limited Deuterated derivatives of ivacaftor
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
AU2013208109A1 (en) 2012-01-09 2014-08-14 Anchor Therapeutics, Inc. APJ receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP2015512947A (ja) 2012-04-13 2015-04-30 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
PL3450434T3 (pl) 2012-06-15 2021-10-04 Concert Pharmaceuticals, Inc. Deuterowane pochodne ruksolitynibu
ES2694202T3 (es) 2012-07-12 2018-12-19 Concert Pharmaceuticals, Inc. Idebenona deuterada
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
CA2895846A1 (en) 2012-12-20 2014-06-26 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
US9789126B2 (en) 2012-12-21 2017-10-17 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EA201892726A1 (ru) 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
AU2014237569B2 (en) 2013-03-15 2019-03-14 Concert Pharmaceuticals Inc. Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
US20160159861A1 (en) 2013-07-18 2016-06-09 Anchor Therapeutics, Inc. APJ Receptor Compounds
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015031741A1 (en) 2013-08-30 2015-03-05 Concert Pharmaceuticals, Inc. Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor
WO2015063670A1 (en) * 2013-10-30 2015-05-07 Wockhardt Limited Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
US9694017B2 (en) 2014-02-10 2017-07-04 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
CA2981791A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
MX2016014890A (es) 2014-06-06 2017-05-01 Res Triangle Inst Agonistas del receptor de apelina (apj) y usos de los mismos.
EP3177292B1 (de) 2014-08-07 2020-11-25 Mayo Foundation for Medical Education and Research Verbindungen und verwendung zur behandlung von krebs
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
CA2994169A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
MA42950A (fr) 2015-09-21 2018-08-01 Vertex Pharmaceuticals Europe Ltd Administration d'agents de potentialisation de cftr modifiés au deutérium
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
KR20180090852A (ko) 2015-12-09 2018-08-13 리써치 트라이앵글 인스티튜트 개선된 아펠린 수용체(apj) 효능제 및 이의 용도
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
JP7145080B2 (ja) 2016-05-04 2022-09-30 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化ｊａｋ阻害剤による脱毛障害の処置
EP3478664B1 (de) 2016-07-04 2020-12-02 Avanir Pharmaceuticals, Inc. Verfahren zur synthese von deuteriertem dextromethorphan
US11596605B2 (en) 2016-08-01 2023-03-07 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
EP3589659A4 (de) 2017-02-28 2021-03-24 Mayo Foundation for Medical Education and Research Verbindungen und verwendung zur behandlung von krebs
WO2018213609A1 (en) 2017-05-17 2018-11-22 Ausubel Frederick M Antibiotic compounds
AU2018270266B2 (en) 2017-05-19 2022-06-30 Superb Wisdom Limited Derivatives of resiquimod
MX2020005336A (es) 2017-11-22 2020-08-13 Concert Pharmaceuticals Inc Analogos de d-serina deuterados y usos de los mismos.
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US20230390292A1 (en) 2020-10-28 2023-12-07 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN118159272A (zh) 2021-08-11 2024-06-07 太阳医药工业公司 用氘化的jak抑制剂来治疗脱发病症
EP4384173A1 (de) 2021-08-12 2024-06-19 Sun Pharmaceutical Industries, Inc. Behandlung von auf jak-hemmung ansprechenden erkrankungen mit prodrugs von jak-hemmern
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20020022056A1 (en) * 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones

Also Published As

Publication number Publication date
HUP0203556A2 (hu) 2003-02-28
ZA200203394B (en) 2003-07-29
TR200200951T2 (tr) 2003-01-21
HU227685B1 (en) 2011-11-28
IL149147A (en) 2010-11-30
DE60039629D1 (de) 2008-09-04
CA2388609A1 (en) 2001-05-10
KR20020049004A (ko) 2002-06-24
CA2388609C (en) 2011-01-04
PL366314A1 (en) 2005-01-24
KR100493836B1 (ko) 2005-06-08
JP2003514780A (ja) 2003-04-22
NO20022058L (no) 2002-06-27
BR0015188A (pt) 2002-11-05
AU777705B2 (en) 2004-10-28
EP1242091B1 (de) 2008-07-23
US20060079502A1 (en) 2006-04-13
EP1242091A2 (de) 2002-09-25
HUP0203556A3 (en) 2004-03-01
CN1407894A (zh) 2003-04-02
MXPA02004389A (es) 2002-09-02
JP2007224041A (ja) 2007-09-06
IL205504A0 (en) 2011-07-31
WO2001032183A2 (en) 2001-05-10
IL149147A0 (en) 2003-01-12
US20090252793A1 (en) 2009-10-08
HK1050839A1 (en) 2003-07-11
SK5842002A3 (en) 2002-08-06
SK287479B6 (sk) 2010-11-08
NO330947B1 (no) 2011-08-22
RU2002113752A (ru) 2004-01-10
CZ302847B6 (cs) 2011-12-14
WO2001032183A3 (en) 2002-07-04
GB9925962D0 (en) 1999-12-29
AU1997801A (en) 2001-05-14
NO20022058D0 (no) 2002-04-30
ES2311001T3 (es) 2009-02-01
CZ20021529A3 (cs) 2002-08-14
NZ518378A (en) 2004-10-29
JP2012211202A (ja) 2012-11-01
HK1050839B (zh) 2009-01-30
US20070037792A1 (en) 2007-02-15
PL200273B1 (pl) 2008-12-31
RU2330666C2 (ru) 2008-08-10

Similar Documents

Publication Publication Date Title
ATE401892T1 (de) Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand
HUP0101293A2 (hu) AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
IL135335A0 (en) Method for inhibiting or preventing hormone induced adverse effects and novel pharmaceutical compositions comprising carotenoids
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
DE10199011I2 (de) ASP-B28-Insulinkristalle.
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
TR200000369T2 (tr) Romatizmal hastalıkların tedavisinde kullanılmak üzere kombine farmasötik preparatların üretilmesi.
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE243196T1 (de) Piperidine und pyrrolidine
ATE292453T1 (de) Antivirale arznei
HK1068606A1 (en) Novel aminobenzoephenones
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
DE50000864D1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
GB0018322D0 (en) Pharmaceutical compositions
DE50005282D1 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
ES2128966A1 (es) Composiciones farmaceuticas parenterales a base de calcitoninas sinteticas, de ph controlado, con bajo indice de dolor y buena estabilidad.
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen
DE69938347D1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242091

Country of ref document: EP